Changes in connectivity in the brain’s white matter may be a novel neuroimaging biomarker for assessing Alzheimer’s disease progression.

Findings from a national study published Nov. 9 in the Journal of the American Medical Association (JAMA) “do not support” the use of hydroxychloroquine for the treatment of adult patients hospitalized with COVID-19, the report concludes.

Hydroxychloroquine (HCQ) did not significantly reduce the incidence of COVID-19 among health care workers who participated in a national study that included Vanderbilt University Medical Center.

How the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative is accelerating development of COVID-19 testing will be the topic of this fall’s second web-based Discovery Lecture.

Diabetes drugs known as GLP-1 receptor agonists, such as exenatide (Byetta), are a promising and safe treatment for a rare form of obesity.

Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.